The FDA just asked a drugmaker to remove its opioid painkiller from the market - and the stock is plunging
The FDA just requested that Endo International take its extended-release opioid painkiller Opana ER (otherwise known as oxymorphone hydrochloride) off the market.
The agency said that the decision came after it found that the drug's benefits no longer outweighed its risk for abuse.
"We are facing an opioid epidemic - a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse," FDA commissioner Scott Gottlieb said in a news release.
More than 183,000 people died from overdoses related to prescription opioid painkillers like oxycodone, hydrocodone, fentanyl, and morphine over the last 15+ years.
Endo's stock was down as much as 12% after-hours on Thursday.
Markets Insider
- Top-selling cars in India in April 2024 – Tata Punch continues to dominate
- Apple Let Loose event today – What to expect, where to watch the live stream and everything you need to know
- Happiest Minds Tech Q4 profit up 25% to ₹72 cr, co hopes to see growth in GenAI vertical
- Uttarakhand forest fire: Poor visibility hampers IAF's firefighting efforts
- A guide on spotting fake reviews and being a savvy online consumer